Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

British Journal of Haematology

Volumn 171, Issue 4, 2015, Pages 471-477

  Sanford, David ^a   Lo Coco, Francesco ^b   Sanz, Miguel A ^c,d   Di Bona, Eros ^e   Coutre, Steven ^f   Altman, Jessica K ^g   Wetzler, Meir ^h   Allen, Steven L ⁱ   Ravandi, Farhad ^a   Kantarjian, Hagop ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e SAN BORTOLO HOSPITAL   (Italy)

^f STANFORD CANCER INSTITUTE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Acute promyelocytic leukaemia; All trans retinoic acid; Arsenic trioxide; Clinical trial; Tamibarotene

Indexed keywords

AMINOTRANSFERASE; ARSENIC TRIOXIDE; LIVER ENZYME; RETINOIC ACID; TAMIBAROTENE; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TETRALIN DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONSCIOUSNESS LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EVENT FREE SURVIVAL; FAINTNESS; FEMALE; FEVER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; INSOMNIA; LEUKEMIA RELAPSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OROPHARYNX PAIN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMYELOCYTIC LEUKEMIA; RASH; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; CLINICAL TRIAL; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; BENZOATES; BIOMARKERS, TUMOR; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; OXIDES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TETRAHYDRONAPHTHALENES; TRETINOIN;

EID: 84945442830     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13607     Document Type: Article

References (17)

1. Adamson, P.C., Boylan, J.F., Balis, F.M., Murphy, R.F., Godwin, K.A., Gudas, L.J. & Poplack, D.G. (1993) Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Research, 53, 472-476.
2. Aribi, A., Kantarjian, H.M., Estey, E.H., Koller, C.A., Thomas, D.A., Kornblau, S.M., Faderl, S.H., Laddie, N.M., Garcia-Manero, G. & Cortes, J.E. (2007) Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 109, 1355-1359.
3. Asou, N., Adachi, K., Tamura, J., Kanamaru, A., Kageyama, S., Hiraoka, A., Omoto, E., Sakamaki, H., Tsubaki, K., Saito, K. & Ohno, R. (1997) All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemotherapy and Pharmacology, 40(Suppl), S30-S35.
4. Cortes, J.E., Kantarjian, H., O'Brien, S., Robertson, L.E., Koller, C., Hirsh-Ginsberg, C., Stass, S., Keating, M. & Estey, E. (1994) All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer, 73, 2946-2952.
5. Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D. & Kantarjian, H. (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 107, 3469-3473.
6. Fang, J., Chen, S.J., Tong, J.H., Wang, Z.G., Chen, G.Q. & Chen, Z. (2002) Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy. Cancer Biology & Therapy, 1, 614-620.
7. Hashimoto, Y., Kagechika, H., Kawachi, E., Fukasawa, H., Saito, G. & Shudo, K. (1995) Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. Journal of Cancer Research and Clinical Oncology, 121, 696-698.
8. Iland, H.J., Bradstock, K., Supple, S.G., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., Reynolds, J., Di Iulio, J., Tiley, C., Taylor, K., Filshie, R., Seldon, M., Taper, J., Szer, J., Moore, J., Bashford, J., Seymour, J.F., Australasian, L. & Lymphoma, G. (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120, 1570-1580; quiz 1752.
9. Kagechika, H., Kawachi, E., Hashimoto, Y., Himi, T. & Shudo, K. (1988) Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. Journal of Medicinal Chemistry, 31, 2182-2192.
10. Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H.R., Cazzola, M., Melillo, L., Carella, A.M., Brandts, C.H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lubbert, M., Hanel, M., Schmitz, N., Link, H., Kropp, M.G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Dohner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Dohner, H., Ehninger, G., Schlenk, R.F. & Platzbecker, U., Gruppo Italiano Malattie Ematologiche, d.A., German-Austrian Acute Myeloid Leukemia Study, G. & Study Alliance, L. (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369, 111-121.
11. Powell, B.L., Moser, B., Stock, W., Gallagher, R.E., Willman, C.L., Stone, R.M., Rowe, J.M., Coutre, S., Feusner, J.H., Gregory, J., Couban, S., Appelbaum, F.R., Tallman, M.S. & Larson, R.A. (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 116, 3751-3757.
12. Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., Ferrajoli, A., Verstovsek, S., Garcia-Manero, G., Cortes, J. & Kantarjian, H. (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of Clinical Oncology, 27, 504-510.
13. Shinagawa, K., Yanada, M., Sakura, T., Ueda, Y., Sawa, M., Miyatake, J., Dobashi, N., Kojima, M., Hatta, Y., Emi, N., Tamaki, S., Gomyo, H., Yamazaki, E., Fujimaki, K., Asou, N., Matsuo, K., Ohtake, S., Miyazaki, Y., Ohnishi, K., Kobayashi, Y. & Naoe, T. (2014) Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. Journal of Clinical Oncology, 32, 3729-3735.
14. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
15. Takeuchi, M., Yano, T., Omoto, E., Takahashi, K., Kibata, M., Shudo, K., Harada, M., Ueda, R. & Ohno, R. (1998) Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leukaemia & Lymphoma, 31, 441-451.
16. Tobita, T., Takeshita, A., Kitamura, K., Ohnishi, K., Yanagi, M., Hiraoka, A., Karasuno, T., Takeuchi, M., Miyawaki, S., Ueda, R., Naoe, T. & Ohno, R. (1997) Treatment with a new synthetic retinoid, Am 80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood, 90, 967-973.
17. Tomita, A., Kiyoi, H. & Naoe, T. (2013) Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. International Journal of Hematology, 97, 717-725.